← All trials
NCT04688320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- Dec 29, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Supergene, LLCLead sponsor
- Pirogov Russian National Research Medical UniversityOverall official - principal investigator
- Supergene, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.